Since 2018, there has been an exponential growth of over US$60 billion of licensing deals involving Antibody Drug Conjugates (ADCs), with 2023 having at least 18 deals. ADCs worldwide are projected to reach US$20-30 billion per year in the near future.

Foley’s Health Care & Life Sciences and Innovative Technology sectors invite you to join us for a webinar on how your organization can navigate the crossroads of ADCs and how you can prepare for this evolving landscape.

This webinar will explore the following:

• An inside look on the U.S. Food & Drug Administration’s (FDA) perspective on ADCs.
• How to prepare and secure your patents and safeguard your ADC intellectual property. 
• The do’s and don’ts of an ADC merger and acquisition.
• Litigation trends in the ADC industry.
• Clinical trial considerations for ADCs.

To register, please click here.

CLE

Applications for accreditation will be submitted to CA, CO, FL, IL, NY, TX, UT, VA, and WI. Uniform Certificates of Attendance will be provided to attendees licensed in other jurisdictions so they may self-apply if their jurisdiction allows.

Foley & Lardner LLP is an approved MCLE provider in California, Colorado, Illinois, New York, Texas, and Utah.

For purposes of New York CLE credit, this program is appropriate for both newly admitted and experienced attorneys. Certificates of attendance will be distributed to eligible participants approximately eight weeks after the program via email.